<DOC>
	<DOCNO>NCT01939093</DOCNO>
	<brief_summary>The aim study compare antipsychotic adverse event quetiapine , atypical antipsychotic drug , haloperidol , standard treatment primary psychotic disorder , individual MAP .</brief_summary>
	<brief_title>Therapeutic Effect Quetiapine Methamphetamine-Induced Psychosis</brief_title>
	<detailed_description>Eighty individual MAP randomly assign two treatment group , i.e . treatment quetiapine haloperidol . The quetiapine group receive quetiapine least 100 mg per day haloperidol group receive haloperidol least 2 mg per day orally day four week . The dos increase every 5 day psychotic symptom observe Positive Negative Syndrome Scale . Common antipsychotic adverse event check documented daily .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Shared Paranoid Disorder</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Thiamine</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Diazepam</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<mesh_term>Cinnarizine</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Having psychotic episode current use methamphetamine Positive urine toxicology test methamphetamine first day hospitalization Using illegal substance Having history primary psychotic disorder use antipsychotic agent Having chronic medical disease , e.g . essential hypertension , diabetes , epilepsy , stroke</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Quetiapine</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Methamphetamine</keyword>
	<keyword>Psychosis</keyword>
</DOC>